AlphaMaven AlphaMaven

Isomorphic's $5b haul, Leo Pharma delays IPO, Lilly keeps shopping

Reported by Axios
Nov 21, 2026· 1 min read
Save Post LinkedIn Email
Key Takeaways
  • • Isomorphic Labs, the AI drug discovery startup led by Demis Hassabis, raised $5 billion in Series C funding, with Greenoaks and Sequoia Capital leading and a16z and Alphabet participating, according to Axios.
  • • Galvanize Therapeutics, a Redwood City, California-based developer of pulsed electric field ablation technologies for oncology and chronic disease, raised a $130 million Series D led by HealthQuest Capital.
  • • Galvanize's round was joined by Olympus Innovation Ventures and Braidwell.
Summary
Axios reports that Isomorphic Labs, an AI-driven drug discovery company led by Demis Hassabis, raised $5 billion in Series C funding. Greenoaks and Sequoia Capital led the round, with a16z and Alphabet also participating. The raise is among the largest private financings in the AI drug discovery sector and underscores continued investor appetite for companies combining machine learning with pharmaceutical research.

In a separate venture capital deal, Galvanize Therapeutics, a Redwood City, California-based developer of pulsed electric field ablation technologies for oncology and chronic disease, raised a $130 million Series D. HealthQuest Capital led the round, joined by Olympus Innovation Ventures and Braidwell.

The primary source summary covers these two financings under the Venture Capital heading. Additional details on the Leo Pharma IPO delay and Eli Lilly's acquisition activity referenced in the headline are not available in the source material provided.

Go deeper than the headline

Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.

Start your free 7-day trial

Sources

1 outlet

AlphaMaven summarised this story from the reporting below. Each link opens the original article.

Axios Isomorphic's $5b haul, Leo Pharma delays IPO, Lilly keeps shopping